Home › Companies › ARCUTIS BIOTHERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and ARCUTIS BIOTHERAPEUTICS INC.’s Form 8-K, filed June 18, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 14, 2024: 5 items on ARCUTIS BIOTHERAPEUTICS INC.’s Form 8-K, filed June 18, 2024: 5 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore ARCUTIS BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ARCUTIS BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Terrie Curran | 77,210,679 | -- | -- | 6,467,280 | 12,428,038 | 92% | Not verified | — |
| Elect Director: Halley Gilbert | 75,828,706 | -- | -- | 7,849,253 | 12,428,038 | 91% | Not verified | — |
| Elect Director: Keith R. Leonard, Jr. | 59,273,804 | -- | -- | 24,404,155 | 12,428,038 | 71% | Not verified | — |
| 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 | 95,949,963 | 6,661 | 149,373 | -- | -- | 99.9% | Not verified | — |
| 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers | 56,906,215 | 26,716,602 | 55,142 | -- | 12,428,038 | 68% | Not verified | — |
Source: ARCUTIS BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on June 18, 2024 — read the filing on EDGAR.
Each item below shows how the 162 asset managers that disclosed a ARCUTIS BIOTHERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Halley E. Gilbert
ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Halley Gilbert”): 75,828,706 for, 7,849,253 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 20,486,006 for, 5,985,660 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Prudential/PGIM | 6,221,017 | 0 | 0 | 0 | For |
| State Street | 13,965 | 0 | 0 | 5,646,093 | Withhold |
| Vanguard | 5,008,236 | 0 | 0 | 0 | For |
| BlackRock | 2,105,305 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,525,545 | 0 | 0 | 0 | For |
| American Century | 967,895 | 0 | 0 | 0 | For |
| Charles Schwab | 751,906 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 636,400 | 0 | 0 | 0 | For |
| JPMorgan | 527,190 | 0 | 0 | 0 | For |
| Fidelity | 311,228 | 0 | 0 | 44,277 | Mixed |
| AMG FUNDS | 310,981 | 0 | 0 | 0 | For |
| T. Rowe Price | 278,221 | 0 | 0 | 0 | For |
| TIAA | 239,497 | 0 | 0 | 0 | For |
| John Hancock | 238,655 | 0 | 0 | 0 | For |
| Federated Hermes | 237,236 | 0 | 0 | 0 | For |
| Equitable | 124,800 | 0 | 0 | 74,700 | Mixed |
| Lincoln Financial | 125,911 | 0 | 0 | 63,100 | Mixed |
| Aberdeen | 148,874 | 0 | 0 | 0 | For |
| ProShares | 141,067 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 136,893 | Withhold |
| SEI | 124,610 | 0 | 0 | 0 | For |
| Invesco | 96,734 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 50,043 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 38,976 | 0 | 0 | 0 | For |
| Brighthouse | 36,705 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 3 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Keith R. Leonard, Jr.
ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Keith R. Leonard, Jr.”): 59,273,804 for, 24,404,155 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 12,952,748 for, 13,518,918 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Prudential/PGIM | 6,221,017 | 0 | 0 | 0 | For |
| State Street | 5,652,086 | 0 | 0 | 7,972 | For |
| Vanguard | 0 | 0 | 0 | 5,008,236 | Withhold |
| BlackRock | 0 | 0 | 0 | 2,105,305 | Withhold |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 1,525,545 | Withhold |
| American Century | 0 | 0 | 0 | 967,895 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 751,906 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 636,400 | Withhold |
| JPMorgan | 0 | 0 | 0 | 527,190 | Withhold |
| Fidelity | 0 | 0 | 0 | 355,505 | Withhold |
| AMG FUNDS | 310,981 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 278,221 | Withhold |
| TIAA | 239,497 | 0 | 0 | 0 | For |
| John Hancock | 198,711 | 0 | 0 | 39,944 | Mixed |
| Federated Hermes | 0 | 0 | 0 | 237,236 | Withhold |
| Equitable | 0 | 0 | 0 | 199,500 | Withhold |
| Lincoln Financial | 63,100 | 0 | 0 | 125,911 | Mixed |
| Aberdeen | 0 | 0 | 0 | 148,874 | Withhold |
| ProShares | 0 | 0 | 0 | 141,067 | Withhold |
| Voya | 136,893 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 124,610 | Withhold |
| Invesco | 96,734 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 50,043 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 38,976 | Withhold |
| Brighthouse | 0 | 0 | 0 | 36,705 | Withhold |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Terrie Curran
ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Terrie Curran”): 77,210,679 for, 6,467,280 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 23,980,412 for, 2,491,254 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Prudential/PGIM | 6,221,017 | 0 | 0 | 0 | For |
| State Street | 5,652,086 | 0 | 0 | 7,972 | For |
| Vanguard | 5,008,236 | 0 | 0 | 0 | For |
| BlackRock | 2,105,305 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,525,545 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 967,895 | Withhold |
| Charles Schwab | 751,906 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 636,400 | Withhold |
| JPMorgan | 527,190 | 0 | 0 | 0 | For |
| Fidelity | 311,228 | 0 | 0 | 44,277 | Mixed |
| AMG FUNDS | 310,981 | 0 | 0 | 0 | For |
| T. Rowe Price | 278,221 | 0 | 0 | 0 | For |
| TIAA | 239,497 | 0 | 0 | 0 | For |
| John Hancock | 208,011 | 0 | 0 | 30,644 | Mixed |
| Federated Hermes | 237,236 | 0 | 0 | 0 | For |
| Equitable | 124,800 | 0 | 0 | 74,700 | Mixed |
| Lincoln Financial | 151,635 | 0 | 0 | 37,376 | Mixed |
| Aberdeen | 0 | 0 | 0 | 148,874 | Withhold |
| ProShares | 0 | 0 | 0 | 141,067 | Withhold |
| Voya | 0 | 0 | 0 | 136,893 | Withhold |
| SEI | 124,610 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 96,734 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 50,043 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 38,976 | Withhold |
| Brighthouse | 0 | 0 | 0 | 36,705 | Withhold |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 11 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”): 56,906,215 for, 26,716,602 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Prudential/PGIM | 6,221,017 | 0 | 0 | 0 | For |
| State Street | 5,652,086 | 7,972 | 0 | 0 | For |
| Vanguard | 0 | 5,008,236 | 0 | 0 | Against |
| BlackRock | 0 | 2,105,305 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 0 | 1,525,545 | 0 | 0 | Against |
| American Century | 0 | 967,895 | 0 | 0 | Against |
| Charles Schwab | 0 | 751,906 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 636,400 | 0 | 0 | Against |
| JPMorgan | 0 | 527,190 | 0 | 0 | Against |
| Fidelity | 0 | 355,505 | 0 | 0 | Against |
| AMG FUNDS | 0 | 310,981 | 0 | 0 | Against |
| T. Rowe Price | 0 | 278,221 | 0 | 0 | Against |
| TIAA | 0 | 239,497 | 0 | 0 | Against |
| John Hancock | 0 | 238,655 | 0 | 0 | Against |
| Federated Hermes | 0 | 237,236 | 0 | 0 | Against |
| Equitable | 0 | 199,500 | 0 | 0 | Against |
| Lincoln Financial | 63,100 | 125,911 | 0 | 0 | Mixed |
| Aberdeen | 0 | 148,874 | 0 | 0 | Against |
| ProShares | 0 | 141,067 | 0 | 0 | Against |
| Voya | 0 | 136,893 | 0 | 0 | Against |
| SEI | 0 | 124,610 | 0 | 0 | Against |
| Invesco | 0 | 96,734 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 50,043 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 38,976 | 0 | 0 | Against |
| Brighthouse | 0 | 36,705 | 0 | 0 | Against |
Fund voting reports, all 49 managers: 11,946,584 for, 14,525,082 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 10,610,814 | 25,911 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,361,285 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 6,821,716 | 0 | 0 | 0 | For |
| State Street | 6,767,005 | 13,540 | 0 | 0 | For |
| Rubric Capital Management LP | 5,312,503 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 0 | 4,432,314 | 0 | 0 | Against |
| Cormorant Asset Management, LP | 2,238,218 | 0 | 0 | 0 | For |
| BlackRock | 34,209 | 1,721,109 | 0 | 0 | Against |
| Bain Capital Life Sciences Investors, LLC | 1,532,237 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 8,229 | 1,348,299 | 0 | 0 | Against |
| FARALLON CAPITAL MANAGEMENT LLC | 0 | 1,185,577 | 0 | 0 | Against |
| American Century | 0 | 999,185 | 0 | 0 | Against |
| JPMorgan | 0 | 931,291 | 0 | 0 | Against |
| Citadel | 778,981 | 0 | 0 | 0 | For |
| J. Goldman & Co LP | 772,186 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 751,906 | 0 | 0 | Against |
| PERCEPTIVE ADVISORS LLC | 736,326 | 0 | 0 | 0 | For |
| Prudential/PGIM | 710,000 | 8,775 | 0 | 0 | For |
| Rafferty Asset Management, LLC | 0 | 636,400 | 0 | 0 | Against |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 627,676 | 0 | 0 | Against |
| HSBC | 0 | 559,330 | 0 | 0 | Against |
| EcoR1 Capital, LLC | 500,000 | 0 | 0 | 0 | For |
| Northern Trust | 400,229 | 898 | 0 | 0 | For |
| T. Rowe Price | 0 | 401,006 | 0 | 0 | Against |
| Eversept Partners, LP | 371,347 | 0 | 0 | 0 | For |
Institutional-manager reports, all 127 managers: 45,295,593 for, 18,025,632 against, 130 not voted. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS, OF ERNST & YOUNG LLP, AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.
ARCUTIS BIOTHERAPEUTICS INC.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 95,949,963 for, 6,661 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 26,471,666 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Prudential/PGIM | 6,221,017 | 0 | 0 | 0 | For |
| State Street | 5,660,058 | 0 | 0 | 0 | For |
| Vanguard | 5,008,236 | 0 | 0 | 0 | For |
| BlackRock | 2,105,305 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,525,545 | 0 | 0 | 0 | For |
| American Century | 967,895 | 0 | 0 | 0 | For |
| Charles Schwab | 751,906 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 636,400 | 0 | 0 | 0 | For |
| JPMorgan | 527,190 | 0 | 0 | 0 | For |
| Fidelity | 355,505 | 0 | 0 | 0 | For |
| AMG FUNDS | 310,981 | 0 | 0 | 0 | For |
| T. Rowe Price | 278,221 | 0 | 0 | 0 | For |
| TIAA | 239,497 | 0 | 0 | 0 | For |
| John Hancock | 238,655 | 0 | 0 | 0 | For |
| Federated Hermes | 237,236 | 0 | 0 | 0 | For |
| Equitable | 199,500 | 0 | 0 | 0 | For |
| Lincoln Financial | 189,011 | 0 | 0 | 0 | For |
| Aberdeen | 148,874 | 0 | 0 | 0 | For |
| ProShares | 141,067 | 0 | 0 | 0 | For |
| Voya | 136,893 | 0 | 0 | 0 | For |
| SEI | 124,610 | 0 | 0 | 0 | For |
| Invesco | 96,734 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 50,043 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 38,976 | 0 | 0 | 0 | For |
| Brighthouse | 36,705 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 115,505,437 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Prudential/PGIM | 5.39% |
| 2 | State Street | 4.90% |
| 3 | Vanguard | 4.34% |
| 4 | BlackRock | 1.82% |
| 5 | FRANKLIN STRATEGIC SERIES | 1.32% |
| 6 | American Century | 0.84% |
| 7 | Charles Schwab | 0.65% |
| 8 | Direxion Shares ETF Trust | 0.55% |
| 9 | JPMorgan | 0.46% |
| 10 | Fidelity | 0.31% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | JENNISON ASSOCIATES LLC | 9.21% |
| 2 | SUVRETTA CAPITAL MANAGEMENT, LLC | 6.37% |
| 3 | Polar Capital Holdings Plc | 5.91% |
| 4 | State Street | 5.87% |
| 5 | Rubric Capital Management LP | 4.60% |
| 6 | FRANKLIN ADVISERS INC | 3.84% |
| 7 | Cormorant Asset Management, LP | 1.94% |
| 8 | BlackRock | 1.52% |
| 9 | Bain Capital Life Sciences Investors, LLC | 1.33% |
| 10 | GW&K Investment Management, LLC | 1.17% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Jennison Associates LLC | 10.50% | DEF14A |
| Prudential Financial, Inc. | 8.56% | DEF14A |
| S | 8.25% | 13G |
| Suvretta Capital Management, LLC | 8.25% | DEF14A |
| Patrick J. Heron | 7.61% | DEF14A |
| Frazier Life Sciences VIII, L.P. | 7.61% | 13D |
| State Street | 7.60% | 13F |
| BlackRock | 7.42% | 13F |
| Vanguard Group | 6.19% | 13F |
| Ruberic Capital Management | 5.75% | DEF14A |
Percentages above are of 115,505,437 shares outstanding, as reported by ARCUTIS BIOTHERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARCUTIS BIOTHERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At ARCUTIS BIOTHERAPEUTICS INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 162 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 893 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 68% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ARCUTIS BIOTHERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2024.
ARCUTIS BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.